DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/34rnw9/rectal_cancer) has announced the addition of the "Rectal Cancer - Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rectal Cancer and special features on late-stage and discontinued projects.
- The report provides a snapshot of the global therapeutic landscape of Rectal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Rectal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
- AbbVie Inc.
- Celltrion, Inc.
- Eisai Co., Ltd.
- GenVec, Inc.
- GlaxoSmithKline plc
- Hanwha Chemical Corporation
- Isofol Medical AB
- Merck & Co., Inc.
- Merck KGaA
- Peregrine Pharmaceuticals, Inc.
- Synta Pharmaceuticals Corp.
For more information visit http://www.researchandmarkets.com/research/34rnw9/rectal_cancer